Allogeneic hematopoietic cell transplantation for lymphoma: baseline and posttransplant prognostic factors

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Oh CM, Won YJ, Jung KW, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2013. Cancer Res Treat. 2016;48:436–450.
   PubMedGoogle Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. JCO. 2010;28:4184–4190.
   PubMed Web of Science ®Google Scholar
• Giulino-Roth L, Ricafort R, Kernan NA, et al. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. Pediatr Blood Cancer. 2013;60:2018–2024.
   PubMed Web of Science ®Google Scholar
• Robinson S, Dreger P, Caballero D, et al. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia. 2015;29:464–473.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Mackinnon S, Linch DC. The role of allogeneic transplantation in non-Hodgkin’s lymphoma. Br J Haematol. 2005;128:153–168.
   PubMed Web of Science ®Google Scholar
• Bhatt VR. Allogeneic stem cell transplantation for non-Hodgkin lymphoma. Curr Hematol Malig Rep. 2016;11:196–207.
   PubMed Web of Science ®Google Scholar
• Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99:1071–1078.
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee JH, Kim DY, et al. A phase II trial of fludarabine/melphalan 100 conditioning therapy followed by allogeneic hematopoietic cell transplantation for patients with lymphoma. Clin Lymphoma Myeloma Leuk. 2015;15:655–663.
   PubMed Web of Science ®Google Scholar
• Lee JH, Joo YD, Kim H, et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. JCO. 2013;31:701–709.
   PubMed Web of Science ®Google Scholar
• Choi SJ, Lee KH, Lee JH, et al. Prognostic value of hematopoietic chimerism in patients with acute leukemia after allogeneic bone marrow transplantation: a prospective study. Bone Marrow Transpl. 2000;26:327–332.
   PubMed Web of Science ®Google Scholar
• Beschorner WE, Tutschka PJ, Santos GW. Chronic graft-versus-host disease in the rat radiation chimera. III. Immunology and immunopathology in rapidly induced models. Transplantation. 1983;35:224–230.
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945–956.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999;94:1465–1470.
   PubMed Web of Science ®Google Scholar
• Stricker BH, Stijnen T. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studes. Eur J Epidemiol. 2010;25:245.
   PubMed Web of Science ®Google Scholar
• Mussetti A, Devlin SM, Castro-Malaspina HR, et al. Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era. Bone Marrow Transpl. 2015;50:1293–1298.
   PubMed Web of Science ®Google Scholar
• Perales MA, Jenq R, Goldberg JD, et al. Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT. Bone Marrow Transpl. 2010;45:1408–1416.
   PubMed Web of Science ®Google Scholar
• Lukenbill J, Hill B. Relapsed/refractory diffuse large B-cell lymphoma: review of the management of transplant-eligible patients. Leuk Lymphoma. 2015;56:293–300.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nimer SD, Glassman JR, et al. The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma. Bone Marrow Transpl. 1999;23:561–567.
   PubMed Web of Science ®Google Scholar
• Fenske TS, Ahn KW, Graff TM, et al. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol. 2016;174:235–248.
   PubMed Web of Science ®Google Scholar
• Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002;100:4310–4316.
   PubMed Web of Science ®Google Scholar
• van Kampen RJ, Canals C, Schouten HC, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin’s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. JCO. 2011;29:1342–1348.
   PubMed Web of Science ®Google Scholar
• Thomson KJ, Morris EC, Milligan D, et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. JCO. 2010;28:3695–3700.
   PubMed Web of Science ®Google Scholar
• van Besien K. Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma. Curr Opin Oncol. 2011;23:681–691.
   PubMed Web of Science ®Google Scholar
• van Besien KW, de Lima M, Giralt SA, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transpl. 1997;19:977–982.
   PubMed Web of Science ®Google Scholar
• Chopra R, Goldstone AH, Pearce R, et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. JCO. 1992;10:1690–1695.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100:406–414.
   PubMed Web of Science ®Google Scholar
• Terwey TH, Le Duc TM, Hemmati PG, et al. NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia. Ann Oncol. 2013;24:1363–1370.
   PubMed Web of Science ®Google Scholar
• Urbano-Ispizua A, Pavletic SZ, Flowers ME, et al. The impact of graft-versus-host disease on the relapse rate in patients with lymphoma depends on the histological subtype and the intensity of the conditioning regimen. Biol Blood Marrow Transpl. 2015;21:1746–1753.
   PubMed Web of Science ®Google Scholar
• Ogonek J, Kralj Juric M, Ghimire S, et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016;7:507.
   PubMed Web of Science ®Google Scholar
• Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood. 2010;115:3861–3868.
   PubMed Web of Science ®Google Scholar
• Chang YJ, Zhao XY, Huo MR, et al. Clinical impact of absolute lymphocyte count on day 30 after unmanipulated haploidentical blood and marrow transplantation for pediatric patients with hematological malignancies. Am J Hematol. 2011;86:227–230.
   PubMed Web of Science ®Google Scholar
• Kim DH, Kim JG, Sohn SK, et al. Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. Br J Haematol. 2004;125:217–224.
   PubMed Web of Science ®Google Scholar
• Kim HT, Armand P, Frederick D, et al. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. Biol Blood Marrow Transpl. 2015;21:873–880.
   PubMedGoogle Scholar
• Yamamoto W, Ogusa E, Matsumoto K, et al. Lymphocyte recovery on day 100 after allogeneic hematopoietic stem cell transplant predicts non-relapse mortality in patients with acute leukemia or myelodysplastic syndrome. Leuk Lymphoma. 2014;55:1113–1118.
   PubMed Web of Science ®Google Scholar
• Afzal S, Ishaqi MK, Dupuis A, et al. Early lymphocyte recovery after allogeneic hematopoietic SCT is associated with significant GVL effect in pediatric ALL but not acute myelogenous leukemia-Update study. Bone Marrow Transpl. 2009;44:799–804.
   PubMed Web of Science ®Google Scholar